

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD  
QUAKERBRIDGE PLAZA, BUILDING 7, Rooms 200 ABC**

July 18, 2018

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

**AGENDA**

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of draft meeting summary for April 18, 2018 meeting
- IV. Secretary's report
- V. Old Business
  - A. Updated protocol for ranolazine (Ranexa<sup>®</sup>)
  - B. Updated protocol for naltrexone (Vivitrol<sup>®</sup>)
  - C. Updated protocol for direct acting antivirals (DAA's) for the treatment of hepatitis C
  - D. Update on gabapentin/opioid combination letter to prescribers
- VI. New Business
  - A. Proposed protocol for safe and efficient use of opioids
  - B. Proposed edit for **prospective** review of high dose opioids >120 mg MME
  - C. Proposed educational newsletter for metformin as first line treatment for T2D
  - D. Medication-Assisted Treatment (MAT) products approval process/access review (injectable naltrexone)
- VII. Informational Highlights/Reports
  - 1. Molina/NJ HMO 1<sup>st</sup> Quarter 2018 Prior Authorization Report
  - 2. Summary of DURB Action Items
  - 3. (a) DHS, DHSS and MCO Programs Top Drugs Report (by amount paid and by category)  
(b) Physician-administered drugs by amount paid/category
  - 4. Medication information:
    - (a) Gabapentin Plus Opioids a Deadly Combination?
    - (b) Help save lives: Co-prescribe naloxone to patients at risk of overdose
    - (c) Alternative Delivery Means Inpatients Get Pain Control With Reduced Opioids
    - (d) Many Young Children Insured by Medicaid Are Prescribed Psychotropic Drugs
    - (e) PPIs may decrease the effectiveness of hepatitis C antivirals